Drug could offer alternative to liver transplant for rare bleeding disorder

This study tested a drug called bevacizumab in 25 adults with hereditary hemorrhagic telangiectasia (HHT) who had severe liver issues and high heart output. The goal was to see if the drug could improve heart function and reduce the need for a liver transplant, which requires lifelong immune-suppressing drugs. Results were measured at 3, 6, and 12 months.